SGP — SpyGlass Pharma, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1778922 ·
Last close
$24.62
Market Cap
$823.49M
52W High
$32.44
52W Low
$17.06
ADV30
128,658
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -21,967,000 | -19,864,000 | 243,433,000 | 223,143,000 | 11,069,000 |
| Mar 2026 | 0 | — | -15,409,000 | -13,818,000 | 258,386,000 | 238,902,000 | 8,274,000 |
| Dec 2025 | 0 | — | -13,627,711 | -12,555,228 | 115,866,000 | 96,358,000 | 214,703,000 |
| Sep 2025 | — | — | — | — | 127,012,143 | 106,006,749 | 214,236,927 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-37,328,736
Investing CF
$2,786,047
Financing CF
$207,103,923
CapEx
$-1,699,466
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.18
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-118,548,000
Inventory
—
Receivables
$653,000
ST Investments
$12,100,000
EBIT TTM
$-44,213,613
Pretax Income TTM
$-43,595,494
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -41,449,000 | -39,869,000 | 115,866,000 | 214,703,000 | -98,837,000 | -32,701,000 |
| Dec 2024 | 0 | -27,064,000 | -29,164,000 | 23,318,000 | 83,792,000 | -60,474,000 | -22,027,000 |
| Dec 2023 | 0 | -14,230,365 | -13,318,990 | 41,149,466 | 74,134,984 | -32,985,518 | -12,277,733 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$258,386,000
Forward EPS
$-2.72
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INMD | InMode Ltd. | $810.22M | $14.08 | — |
| SIBN | SI-BONE, Inc. | $845.28M | $18.86 | — |
| BBNX | Beta Bionics, Inc. | $784.17M | $17.43 | — |
| BVS | Bioventus Inc. | $866.79M | $12.69 | — |
| CBLL | Ceribell, Inc. | $888.45M | $23.15 | — |
News headlines (Yahoo Finance, 1h cache)
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
2026-10-01 12:00 · Yahoo
SpyGlass Pharma to Participate in Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space
2026-08-27 20:40 · Yahoo
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
2026-06-02 12:00 · Yahoo
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
2026-05-18 12:00 · Yahoo
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-14 20:05 · Yahoo
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
2026-08-06 20:05 · Yahoo
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
2026-06-15 12:00 · Yahoo
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
2026-03-26 20:05 · Yahoo
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
2026-03-09 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.